-
Product Insights
NewNet Present Value Model: Akeso Inc’s Ivonescimab
Empower your strategies with our Net Present Value Model: Akeso Inc's Ivonescimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Akeso – Shanghai Global R&D Center – Shanghai
The Akeso – Shanghai Global R&D Center – Shanghai project involves the construction of a global research and development (R&D) center at the Zhangjiang Headquarters Park in Shanghai, China. Equip yourself with the essential tools needed to make informed and profitable decisions with our Akeso – Shanghai Global R&D Center – Shanghai report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Manfidokimab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Manfidokimab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Manfidokimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Manfidokimab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AK-127 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AK-127 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AK-127 in Solid Tumor Drug Details: AK-127 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitazoxanide in Acute On Chronic Liver Failure (ACLF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nitazoxanide in Acute On Chronic Liver Failure (ACLF) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nitazoxanide in Acute On Chronic Liver Failure...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONL-1204 in Retinal Pigment Epithelial (RPE) Detachment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONL-1204 in Retinal Pigment Epithelial (RPE) Detachment report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONL-1204 in Retinal Pigment Epithelial (RPE) Detachment Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Barzolvolimab in Prurigo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Barzolvolimab in Prurigo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Barzolvolimab in Prurigo Drug Details: Barzolvolimab (CDX-0159) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Padnarsertib in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Padnarsertib in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Padnarsertib in Relapsed Acute Myeloid Leukemia Drug Details: KPT-9274...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Growth Hormone Deficiency Drug Details: Ibutamoren...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ligufalimab in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ligufalimab in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ligufalimab in Myelodysplastic Syndrome Drug Details: Ligufalimab is under development for...